Molecular differences in transition zone and peripheral zone prostate tumors. Academic Article uri icon

Overview

abstract

  • Prostate tumors arise primarily in the peripheral zone (PZ) of the prostate, but 20-30% arise in the transition zone (TZ). Zone of origin may have prognostic value or reflect distinct molecular subtypes; however, it can be difficult to determine in practice. Using whole-genome gene expression, we built a signature of zone using normal tissue from five individuals and found that it successfully classified nine tumors of known zone. Hypothesizing that this signature captures tumor zone of origin, we assessed its relationship with clinical factors among 369 tumors of unknown zone from radical prostatectomies (RPs) and found that tumors that molecularly resembled TZ tumors showed lower mortality (P = 0.09) that was explained by lower Gleason scores (P = 0.009). We further applied the signature to an earlier study of 88 RP and 333 transurethral resection of the prostate (TURP) tumor samples, also of unknown zone, with gene expression on ~6000 genes. We had observed previously substantial expression differences between RP and TURP specimens, and hypothesized that this might be because RPs capture primarily PZ tumors, whereas TURPs capture more TZ tumors. Our signature distinguished these two groups, with an area under the receiver operating characteristic curve of 87% (P < 0.0001). Our findings that zonal differences in normal tissue persist in tumor tissue and that these differences are associated with Gleason score and sample type suggest that subtypes potentially resulting from different etiologic pathways might arise in these zones. Zone of origin may be important to consider in prostate tumor biomarker research.

publication date

  • April 13, 2015

Research

keywords

  • Biomarkers, Tumor
  • Gene Expression Regulation, Neoplastic
  • Prostate
  • Prostatic Neoplasms

Identity

PubMed Central ID

  • PMC4572920

Scopus Document Identifier

  • 84941647815

Digital Object Identifier (DOI)

  • 10.1093/carcin/bgv051

PubMed ID

  • 25870172

Additional Document Info

volume

  • 36

issue

  • 6